Merck KGaA has signed a definitive agreement to divest its CDMO business to Lonza for a mid-triple-digit million-euro amount. The deal covers five US-based operations and is expected to close in mid-2027.
The Merck Daejeon bioprocessing center opened on 29 October 2026 with a €300 million-plus investment, adding cell culture media, process liquids and sterile sampling capacity for Asia-Pacific biopharma manufacturers.
Sandoz 2026 sales reached USD 8,703 million in the first nine months, up 5% at constant currencies, with biosimilars up 19% and generics down 1%. The company narrowed full-year net-sales growth guidance to 5-6% and upgraded its core-EBITDA margin outlook to 23.0-23.5%.
Samsung Biologics Q3 2026 Results show revenue of KRW 1,490 billion and operating profit of KRW 640 billion. Plant 5 ramp-up and the Rockville site contributed, and the company raised its 2026 revenue growth guidance to 20%.
Charles River Laboratories has completed automation of its Endosafe Cartridge Technology manufacturing suite in Wilmington, Massachusetts, reporting double-digit gains in productivity, capacity and product consistency ahead of full operational scale-up in Q3 2026.
Genentech, Roche’s US subsidiary, will invest approximately $750 million to build a new device fill-finish facility at its Hillsboro, Oregon campus, adding 250 manufacturing jobs and doubling the site’s size ahead of a 2031 commercial start.
Samsung Biologics Q2 2026 earnings rose year-over-year to KRW 1,321 billion in revenue and KRW 586 billion in operating profit, as the CDMO advanced its Rockville facility integration, Plant 5 ramp-up, and pending PolyPeptide Group acquisition.
WuXi Biologics’ MFG8 facility in Hebei has successfully cleared a rigorous seven-day U.S. FDA Pre-License Inspection. This crucial WuXi Biologics FDA PLI Approval paves the way for the scaled commercial supply of a highly anticipated blockbuster autoimmune therapy, reinforcing the company’s unblemished 100% FDA PLI success rate and robust global quality standards.
Merck delivers a robust Q1 2026 performance with €5.1 billion in sales. Driven by its Life Science and Electronics sectors, the company has officially upgraded its full-year outlook.
Samsung Biologics reports a stellar start to 2026, recording KRW 1,257 billion in revenue and KRW 581 billion in operating profit, fueled by its new U.S. manufacturing presence and Plant 4 utilization.
